Enjoy complimentary customisation on priority with our Enterprise License!
The Obsessive-Compulsive Disorder (OCD) Drugs Market size is estimated to grow by USD 348.54 million at a CAGR of 5.93% between 2023 and 2028.
Conventional therapies used to treat OCD are anti-anxiety, antipsychotic, and antidepressant drugs, along with behavioral therapies and psychotherapy. However, these medications and therapies are only for short-term treatment. In the long term, OCD can be managed but cannot be cured completely without patient compliance. Antidepressants classified as SRI have been used to treat OCD for many years. Hence, the Anafranil SRI molecule is considered the drug of choice for treating OCD. Anafranil was approved by the US FDA to treat OCD in adults and children aged ten and above. Similarly, to treat treatment-resistant depression, various vendors are developing new products. For instance, Jazz Pharmaceuticals plc offers LUVOX CR, which is available for patients with social anxiety disorder and OCD. Such launch and development of new molecules are expected to boost the market growth and trends during the forecast period.
Technavio has segmented the market into Product, Route Of Administration and Geography
It also includes an in-depth analysis of market research and growth and trends along with challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Download Report Sample
The market share growth by the SSRI segment will be significant during the forecast period. The availability of a large number of SSRIs in the market, such as fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram driven the growth of the segment. These drugs act through selective inhibition of presynaptic serotonin or 5-hydroxytryptamine (5-HT) reuptake transport system, which increases the levels of serotonin in the brain.
Get a glance at the market contribution of various segments Download PDF Sample
The SSRI was the largest and was valued at USD 388.38 million in 2018. SSRIs are the first-line treatment for OCD due to fewer side effects compared with TCA and other classes of drugs. For instance, unlike SSRIs, TCA causes severe withdrawal symptoms and suicidal risks. This is due to the selective inhibition of 5-HT reuptake in presynaptic junctions. Hence, SSRIs are preferred over TCA and other segment drugs in treating OCD. Among SSRIs, fluoxetine, sertraline, and fluvoxamine are approved for pediatric patients with OCD. Major countries and some organizations, like the US, the European Union (EU), and Japan, have approved many generic versions due to the high demand for SSRIs. Some companies are developing controlled-release and sustained-release formulations of SSRIs. Such new drugs are expected to accelerate the growth of the global OCD drugs market during the forecast period.
One popular and useful way to administer drugs, including those used to treat OCD, is orally. Within the market for OCD pharmaceuticals, oral administration refers to taking medication by mouth; they are usually tablets, capsules, or liquid formulations. The active components required to treat OCD symptoms are present in these solid dose forms. Certain drugs are supplied in capsule form, which has a powdered or liquid drug within. The precise dosage and simplicity of ingesting are two benefits of using capsules. Although oral administration is commonly employed in the market for OCD medications, it is important to remember that other administration methods, such as intravenous or transdermal, may be taken into consideration depending on the needs of a particular patient and the medication's properties. The drug characteristics, the patient preferences, and the intended treatment all influence the route of administration that is selected. Therefore, the oral segment will witness high growth, which in turn will drive the growth of the global OCD drugs market during the forecast period.
When medication is administered parenterally, the digestive tract is skipped, and the drug is absorbed straight into the body. Parenteral administration is less common than oral administration in the context of OCD drug sales, but it can be used in certain situations. Subcutaneous, intramuscular, and intravenous injections are only a few of the injection routes that can be used for parenteral administration. The medicine is injected straight into a vein during intravenous delivery. Parenteral administration is not the preferred method for administering most OCD medications, but it might be taken into consideration in specific clinical scenarios. The patient's condition, the urgency of the treatment, and the particulars of the medication all play a role in the decision between oral and parenteral administration. Healthcare practitioners thoroughly consider these aspects to ascertain the best way to administer OCD medications in each unique situation. Hence, parenteral administration is less applicable in the global OCD
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 55% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The obsessive-compulsive disorder (OCD) drugs market growth in North America is attributed to three major drivers, which include the growing incidence of OCD, government initiatives to combat OCD, and the availability of drugs. The rising incidence of OCD in the US and Canada is driving obsessive-compulsive disorder drugs market growth in North America. The presence of a large number of OCD drugs in the US and Canada is driving the obsessive-compulsive disorder drugs market in North America.
For instance, as of December 2021, the US FDA approved more than 150 products, including the NDA and ANDA versions of fluoxetine. Similarly, the US FDA approved more than 80 products, including the NDA and ANDA versions of paroxetine. Similarly, Apotex Inc. offers Paroxetine Hydrochloride Tablets USP for the treatment of OCD. Eli Lilly and Co. offers Prozac (fluoxetine) in 10, 20, and 40 mg capsules. Thus, the availability of a large number of drugs is expected to propel the regional OCD drugs market during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Anant Pharmaceuticals Pvt. Ltd. - The company offers obsessive compulsive disorder drugs under the brand name of Celexa, and Luvox
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the market growth and forecasting along with key drivers, trends, and challenges.
The rising prevalence of OCD is notably driving market growth. The prevalence of OCD is high in high-income countries due to the drastic change in the lifestyle of individuals. For instance, exposure to motion picture technologies provokes individuals about imaginary images, intrusive thoughts, and urges. OCD is considered the fourth most common mental disorder in high-income countries. OCD affects men, women, and children. It is most evident in childhood, adolescence, or early adulthood stages.
For instance, as per the NIH, approximately three million adults in the US have OCD. Among children and teenagers, at least one in 200 or 500,000 individuals have the disorder, and the number is almost the same as that of children with diabetes. Such a high prevalence of the disorder is expected to drive the growth of the global OCD drugs market during the forecast period.
Expanding research on first-in-class peptide therapeutics is an emerging trend shaping the market growth during the market forecast. The development of a new class of peptide therapeutics research is to enhance the bioavailability of the products and to address the unmet needs of OCD, such as the lack of new drugs. For instance, troriluzole is a third-generation tripeptide prodrug molecule that modulates the glutamate neurotransmitter in the human body. The prodrug form enhances the bioavailability of the riluzole by getting absorbed through the peptide transporter 1.
As a result, the troriluzole molecule is expected to be approved over the forecast period with improved pharmacological activity, safer dosage, and enhanced bioavailability. Similarly, Omeros Corp. developed a phase I molecule, OMS-527. Such new drug developments are expected to propel the growth of the market during the forecast period.
Adverse reactions to OCD drugs are a significant challenge hindering market growth. The low-quality, inexpensive kettle controls developed by the Chinese manufacturers are adversely affecting consumers' health. Owing to the rising number of issues from consumers and other global vendors in the market, the Chinese government has introduced regulations to improve the quality of such products. As a result, many Chinese products have been called off from the market.
Moreover, most of the prominent vendors have limited supply to commercial kitchens and underdeveloped regions, it is limiting the revenue flow in the market and limiting the entry of new vendors. Thus, the Increasing health concerns due to the poor quality of electric kettles will hamper the growth of the global kettle controls market during the forecast period.
The market analysis and report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Obsessive-Compulsive Disorder Drugs Market Customer Landscape
The obsessive-compulsive disorder drugs Market forecasting report, market trends and analysis and market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Obsessive-Compulsive Disorder Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
159 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.93% |
Market growth 2024-2028 |
USD 348.54 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.18 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 55% |
Key countries |
US, Germany, France, China, and Japan |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Alembic Pharmaceuticals Ltd., Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., BrainsWay Ltd., Dellwich Healthcare LLP, Eli Lilly and Co., Eridanus, flamingopharma.com, GlaxoSmithKline Plc, H Lundbeck AS, Jabs Biotech, Jazz Pharmaceuticals Plc, Kabir Lifesciences, Lepu Medical Technology Beijing Co. Ltd., Lifecare Neuro Products Ltd., Novartis AG, Omeros Corp., Pfizer Inc., SERVOMAX Ltd., Wellona Pharma, and Neurocon Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.